Table 1 Characteristics of LOPD patients and healthy volunteers

From: Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease

 

HV n = 10

LOPD n = 10

Female, (%)

5 (50)

5 (50)

Male (%)

5 (50)

5 (50)

Age, years

41.2 ± 14.2

40.6 ± 12.1

Weight, kg

73.9 ± 11.9

65.0 ± 17.3

Height, cm

176.2 ± 0.1

172.3 ± 0.1

BMI (kg/m2)

23.6 ± 2.2

21.6 ± 4.0

Ambulatory (%)

10 (100)

9 (90)

ERT (%)

0 (0)

8 (80)

Nocturnal ventilation support

0 (0)

4 (40)

Lung function

  

FEV1 (%)

100.8 ± 11.8

68.2 ± 23.5

FVC (%)

104.9 ± 9.7

62.6 ± 21.4

Functional testing

  

R-PACT

36.0 ± 0.0

29.1 ± 10.4

QMFT

64 ± 0.0

46.7 ± 16.1

6MWT (m)

671.3 ± 116.6

560.3 ± 87.2

TUAG (s)

1.7 ± 0.4

3.7 ± 3.0

MRC

UB

Proximal

5.0 ± 0.0

4.3 ± 0.1

Medial

5.0 ± 0.0

4.5 ± 0.1

Distal

5.0 ± 0.0

4.7 ± 0.0

LW

Proximal

5.0 ± 0.0

3.9 ± 0.1

Medial

5.0 ± 0.0

4.1 ± 0.1

Distal

5.0 ± 0.0

4.5 ± 0.1

  1. Values are mean ± standard deviation (SD).
  2. LOPD late-onset Pompe disease, HV healthy volunteer, BMI body mass index, ERT enzyme replacement therapy, FEV1 forced expiratory volume, FVC functional vital capacity, R-Pact Rasch-built Pompe-specific activity score, QMFT quick motor function test, 6MWT 6-min walking test, TUAG timed up-and-go test, MRC Medical Research Council score, UB upper body, LB lower body, SD standard deviation.